Illumina provides integrated sequencing platforms and related consumables for analyzing genetic variation and biological function. Its instruments range from high-throughput NovaSeq systems to benchtop MiSeq/iSeq units, all built on sequencing-by-synthesis technology acquired from Solexa. Revenue comes from instrument sales plus a recurring stream of consumables, reagents, library preparation kits, and services. The company differentiates itself with a broad end-to-end ecosystem and strategic acquisitions (Solexa, GRAIL, SomaLogic) that expand capabilities into multiomics and clinical diagnostics.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1998
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Bernstein keeps their Hold rating on Illumina (ILMN). Sep. 26, 2026, 08:55 AM Bernstein analyst Eve Burstein maintained a Hold rating on Illumina yesterday and set a price target of $215.00. The company's shares closed yesterday at $270.00. According to TipRanks, Burstein is a 5-star analyst with an average return of 27.5% and a 78.00% success rate. Burstein covers the Healthcare sector, focusing on stocks such as Agilent, Thermo Fisher, and Waters. In addition to Bernstein, Illumina also received a Hold from Canaccord Genuity's Kyle Mikson CFA in a report issued on September 11. However, on September 15, Stifel Nicolaus maintained a Buy rating on Illumina (NASDAQ: ILMN). Based on Illumina's latest earnings release for the quarter ending June 28, the company reported a quarterly revenue of $1.16 billion and a net profit of $207 million. In comparison, last year the company earned a revenue of $1.06 billion and had a net profit of $235 million Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ILMN in relation to earlier this year. Earlier this month, Keith Meister, a Director at ILMN sold 263,560.00 shares for a total of $57,199,200.67. Read More on ILMN:
People in the news. GenomeWeb tracks the career moves of prominent people in the fields of genetics, genomics, diagnostics, and precision medicine. People in the news for the week of Sept. 21, 2026: Nimisha Srivastava, Glenn Bilawsky, Doug White, Vijay Singh, Carl Raimond, Michael Chen, David Horn, Charles Endweiss September 25, 2026 09:32 AM EDT Nimisha Srivastava has been promoted to CEO of Slingshot Biosciences, replacing Glenn Bilawsky. September 25, 2026 06:04 AM EDT Astek Diagnostics has appointed Doug White the executive chairman of its board. September 24, 2026 10:10 AM EDT Vijay Singh has been appointed as CSO of the life sciences tools division of Longhorn Vaccines and Diagnostics. September 22, 2026 06:25 PM EDT Carl Raimond has been appointed as CEO of Nuclera. September 22, 2026 10:13 AM EDT Seer announced the firm's President, CFO, and Treasurer David Horn is leaving Seer. Charles Endweiss will take over as treasurer, principal financial officer, and principal accounting officer. September 21, 2026 09:16 AM EDT Joel Fellis is leaving Illumina, where he has been serving as VP of strategic innovation. September 17, 2026 05:21 PM EDT Astrin Biosciences has appointed Tanya Gupta as medical director. September 17, 2026 03:54 PM EDT VedaBio has appointed Valerie Dixon as the first independent member of its board of directors. September 17, 2026 03:37 PM EDT Josh Denny will step down as CEO of the National Institutes of Health's All of Us Research Program on Oct. 31, after almost seven years, to take up a leadership position at the University of Chicago. September 16, 2026 03:31 PM EDT
AI accelerator cards reshape DNA sequencing workflows. The global market for AI DNA sequencer base-calling accelerator cards is expanding as genomics workflows require faster, more accurate nucleotide identification. These specialized compute modules offload signal processing and deep-learning inference from host CPUs, reducing data-transfer bottlenecks and enabling on-instrument analytics that once depended on large data-center environments. Growth is tied to rising sequencing demand, with sequencing expenditures projected to surpass US$ 30 billion annually. Long-read and single-cell applications are increasing the need for flexible AI-optimized compute, while clinical diagnostics, research and development, and personalized medicine are key application areas. On-premise integration, cloud-connected systems, and hybrid edge deployments are shaping adoption models. NVIDIA, Intel, Illumina, and Thermo Fisher Scientific lead the competitive field through GPU, ASIC, FPGA, and platform-specific approaches. Illumina has introduced the NovaBase AI card, while Thermo Fisher Scientific offers the Ion Torrent Accelerate Card. AMD, Xilinx, Hewlett Packard Enterprise, Cisco, Qualcomm, IBM, Pacific Biosciences, Oxford Nanopore Technologies, Roche Sequencing Solutions, BGI Genomics, and QIAGEN are pursuing specialized roles across the ecosystem. Europe is positioned as a highly advanced market due to strong research networks, privacy regulation, and sustainability priorities. North America benefits from federal research funding and biotech activity, while Asia-Pacific shows strong potential through expanding genomics infrastructure in China, Japan, South Korea, and India.
Illumina will join the S&P 500 index on 21 September, alongside Bloom Energy and Everpure, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource. S&P Dow Jones Indices announced the rebalancing on Friday. The San Diego-based genetic sequencing company, valued at $33 billion, has returned 112% over the past 12 months. The inclusion will trigger buying from passive funds tracking the index. Illumina is moving from the S&P MidCap 400, signalling its growth into large-cap status. In the second quarter, the company reported revenue of $1.16 billion, up 9.5% year-over-year, with earnings per share rising approximately 10% to $1.31.
Illumina reported second-quarter revenues of $1.16 billion, marking a 9.4% year-on-year increase that exceeded analyst expectations by 2.5%. The DNA sequencing and microarray technology company delivered strong organic revenue performance and raised its full-year earnings guidance. Chief executive Jacob Thaysen attributed the results to growing momentum in sequencing-intensive applications among clinical customers. The company increased its revenue and earnings guidance for the year based on this performance. Illumina's shares rose 10% following the earnings announcement and currently trade at $225.55. The results came as part of a strong second quarter for the life sciences tools and services sector overall, with the 20 tracked stocks in the group beating revenue estimates by 2.6% on average.